Key opinion leaders highlight the MS treatment landscape. Ryan Haumschild, PharmD, MS, MBA: Now that we’ve talked about the background of multiple sclerosis [MS] in detail, I think it’s important for ...

Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. Speaking to Fierce Pharma, CEO Daniel Vitt shares insights ...

A team from UNIGE and HUG has discovered a subgroup of immune cells particularly involved in the disease, opening the way to ...

MS can occur at any age and presents itself more frequently in females than in males (69% vs. 31%). Current treatments for the condition reduce its relapse rate, but there is still an unmet need to ...

BTK inhibitor implementation for MS treatment is explored. Ryan Haumschild, PharmD, MS, MBA: Now if we could, let’s discuss the emerging role of Bruton tyrosine kinase inhibitors [BTKis] in multiple ...

Multiple sclerosis (MS) is a chronic disease of the nervous system that can lead to muscle weakness, vision loss, and paralysis. It occurs when the immune system attacks the myelin sheath that ...

In MS, immune system cells mistakenly attack myelin. With stem cell treatment, doctors use chemotherapy to destroy these existing immune cells. Then, they introduce the new stem cells, which are not ...

An international panel of experts has proposed a new way to classify multiple sclerosis (MS) that would ultimately change the way patients are diagnosed and treated. The goal is to eventually move ...

Pre-clinical studies using a small molecule drug have shown promise as a potential new treatment for multiple sclerosis (MS). CAMH-led pre-clinical studies using a small molecule drug have shown ...

Neurologists have found in a recent study that common drugs to treat multiple sclerosis lead to modest health benefits but very high costs, according to a news release from Kirkland, Wash.-based ...

Improvements in safety, efficacy, and specificity have raised questions around the benefits and risks of switching treatments for this type of MS, especially from fingolimod to siponimod. There are ...

Initiating treatment for multiple sclerosis (MS) within 6 months of the first symptoms is associated with a significantly lower risk for severe disability one decade later, a new study suggests.